Literature DB >> 11571736

Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma.

A Thylén1, A Hjerpe, G Martensson.   

Abstract

BACKGROUND: Regardless of the modality of therapy used, malignant pleural mesothelioma is a highly treatment-resistant and invariably fatal disease. Identification of prognostic variables are important for future investigational therapeutic studies.
METHODS: The prognostic significance of various clinical variables, including hyaluronan levels in pleural fluid, was evaluated in a retrospective analysis in 100 patients with histologically confirmed malignant pleural mesothelioma.
RESULTS: The overall median survival was 11.5 months. Univariate analyses identified histologic subtype, i.e., epithelial or mixed, and elevated content of hyaluronan in the pleural effusion as significant prognostic variables. A multivariate analysis confirmed the independent predictive power of histologic subtype, and an elevated concentration of hyaluronan in the pleural fluid also indicated longer survival in older patients and in patients receiving therapy other than supportive.
CONCLUSIONS: The prognostic value of histologic subtype and the concentration of hyaluronan in pleural effusions should be considered when designing and evaluating treatment trials for patients with malignant pleural mesothelioma. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11571736     DOI: 10.1002/1097-0142(20010901)92:5<1224::aid-cncr1441>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions.

Authors:  L Welker; M Müller; O Holz; E Vollmer; H Magnussen; R A Jörres
Journal:  Virchows Arch       Date:  2007-02-15       Impact factor: 4.064

Review 2.  Methods for isolating and analyzing physiological hyaluronan: a review.

Authors:  Felipe Rivas; Dorothea Erxleben; Ian Smith; Elaheh Rahbar; Paul L DeAngelis; Mary K Cowman; Adam R Hall
Journal:  Am J Physiol Cell Physiol       Date:  2022-02-23       Impact factor: 4.249

3.  Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma.

Authors:  Takeshi Hanagiri; Shinji Shinohara; Masaru Takenaka; Yoshiki Shigematsu; Manabu Yasuda; Hidehiko Shimokawa; Yoshika Nagata; Makoto Nakagawa; Hidetaka Uramoto; Tomoko So; Fumihiro Tanaka
Journal:  Tumour Biol       Date:  2012-08-11

Review 4.  Malignant mesothelioma: current status and perspective in Japan and the world.

Authors:  Seiki Hasegawa; Fumihiro Tanaka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-07-08

Review 5.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

6.  Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.

Authors:  Filip Mundt; Gustav Nilsonne; Sertaç Arslan; Karola Csürös; Gunnar Hillerdal; Huseyin Yildirim; Muzaffer Metintas; Katalin Dobra; Anders Hjerpe
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

7.  Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.

Authors:  Adam Szulkin; Rita Otvös; Carl-Olof Hillerdal; Aytekin Celep; Eviane Yousef-Fadhel; Henriette Skribek; Anders Hjerpe; László Székely; Katalin Dobra
Journal:  BMC Cancer       Date:  2014-09-24       Impact factor: 4.430

Review 8.  Prognostication and monitoring of mesothelioma using biomarkers: a systematic review.

Authors:  David T Arnold; Duneesha De Fonseka; Fergus W Hamilton; Najib M Rahman; Nick A Maskell
Journal:  Br J Cancer       Date:  2017-02-07       Impact factor: 7.640

9.  Fra-1 governs cell migration via modulation of CD44 expression in human mesotheliomas.

Authors:  Maria E Ramos-Nino; Steven R Blumen; Harvey Pass; Brooke T Mossman
Journal:  Mol Cancer       Date:  2007-12-21       Impact factor: 27.401

10.  Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.

Authors:  Marco Tomasetti; Lory Santarelli
Journal:  Cancers (Basel)       Date:  2010-04-14       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.